JNJ's Consistent Payout Makes It a Top Pick for Down Markets
The company is facing a combination of slow revenue growth, unresolved legal battles over talc products, and looming drug price negotiations under new Medicare rules.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 8,708,762 | $1,444,261,119 | +7% | 0.63% |
| 2. | AQR Capital Management Cliff Asness | 5,265,710 | $873,265,458 | +52% | 0.9% |
| 3. | 5,001,500 | $829,448,760 | +32% | 0.16% | |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,301,356 | $547,496,879 | +40% | 0.44% |
| 5. | 2,607,600 | $432,444,384 | +47% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing | |
| $139.68 | 3,000 | $419,040.00 | 3,000 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.88 | 6,999 | $1,160,994.12 | 21,001 | 2025-02-25 | Filing | |
| $156.15 | 403 | $62,928.45 | 15,098 | 2025-02-18 | Filing | |
| $153.89 | 13,015 | $2,002,878.35 | 0 | 2025-02-07 | Filing | |
| $165.06 | 5,635 | $930,113.10 | 18,973 | 2024-08-30 | Filing | |
| $162.16 | 8,891 | $1,441,764.56 | 15,043 | 2024-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 233,962,679 | $38,800,370,685 | 0.7% | |
| 2. | 199,366,959 | $33,063,016,595 | 0.69% | |
| 3. | 133,789,785 | $22,187,697,944 | 0.91% | |
| 4. | 59,383,800 | $9,826,834,590 | 0.77% | |
| 5. | 54,061,842 | $8,965,616,159 | 0.65% |
News See All
10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
Blue-chip stocks are great assets for investors looking for opportunities to grow their capital in the long term. Some call them steady oaks in the forest of finance.
Johnson & Johnson (JNJ) Announces Results for Phase 3b APEX Study
Johnson & Johnson (NYSE:JNJ) is one of the 10 Cheapest High-Quality Stocks to Buy According to Hedge Funds.
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader...
Retirement Stock Portfolio: 10 Safe Dividend Stocks to Buy Now
Dividend-paying stocks are often considered a dependable option for retirement portfolios.
10 Cheapest High Quality Stocks to Buy According to Hedge Funds
On June 4, Jurrien Timmer, director of Global Macro for Fidelity Management & Research Company released his commentary on the stock market outlook.
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support...
Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index
The Dow Jones Industrial Average, often called the Dow Jones or just the Dow, is a stock market index that tracks 30 major publicly traded companies in the United States.
US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson's DARZALEX FASPRO
On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase...
Jim Cramer Notes That "People Are Staying Away From" Johnson & Johnson
“Or let's consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises ...
Billionaire Hedge Funds
